Eli Lilly To Present New Data On Olumiant (Baricitinib) In Rheumatoid Arthritis And Taltz (Ixekizumab) In Psoriatic Arthritis At The Annual European Congress Of Rheumatology (EULAR 2017)

INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be presented in 21 abstracts, including one oral presentation, at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid, June 14-17, 2017.

Lilly will also present six abstracts evaluating Taltz® (ixekizumab) for the treatment of psoriatic arthritis (PsA), including two oral presentations highlighting data from two Phase 3 studies (SPIRIT-P1 and SPIRIT-P2).

Additionally, Lilly will present two abstracts from its ongoing research to advance the understanding of rheumatologic diseases. One abstract is focused on the relationship between the degree of skin involvement and joint activity in patients with PsA based on information from the Corrona® registry, and the other abstract is on the symptomology, disease status and remission rate of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients in Europe.

"Rheumatoid arthritis, psoriatic arthritis and psoriasis are chronic, debilitating diseases that significantly impact the physical wellbeing of millions of people worldwide, many of whom are not currently achieving their treatment goals with existing therapies," said J. Anthony Ware, M.D., senior vice president, product development, Lilly Bio-Medicines. "We are excited to present new data for Olumiant and Taltz at EULAR 2017, all of which highlight our commitment to the ongoing research and development of innovative therapies for people living with these immune-mediated diseases."

Back to news